Plain-English translation of NCT05991895 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a real-world study that tracks how well works for people with ALK-positive non-small cell lung cancer. The researchers will gather information from your existing medical records and treatment history to understand the medication's effectiveness and safety in actual clinical practice, rather than in a controlled experiment.
While medications are tested in controlled trials before approval, doctors and patients need to know how well treatments actually work for diverse patients in everyday medical care. This study fills that gap by collecting real-world data to better understand this medication's benefits and any side effects patients experience.
You won't need to make extra visits or change your treatment plan. Instead, researchers will review your existing medical records and information about how you responded to the medication and any side effects you experienced. Your doctor's routine follow-up visits and standard care will continue as normal—the study simply gathers that information to analyze real-world treatment outcomes.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China
Enrollment target
~5,000 participants
Started
July 2023
Primary completion
July 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jinming Yu, PhD
Shandong Cancer Hospital and Institute